Suppr超能文献

椎间盘内治疗是否与临床改善相关?随机对照研究的比较。

Is There Clinical Improvement Associated With Intradiscal Therapies? A Comparison Across Randomized Controlled Studies.

作者信息

Ju Derek G, Kanim Linda E, Bae Hyun W

机构信息

Cedars-Sinai Medical Center, Los Angeles, CA, USA.

出版信息

Global Spine J. 2022 Jun;12(5):756-764. doi: 10.1177/2192568220963058. Epub 2020 Oct 13.

Abstract

STUDY DESIGN

Post hoc comparison using single-site data from 4 multicenter randomized controlled trials.

OBJECTIVES

Discogenic back pain is associated with significant morbidity and medical cost. Several terminated, unreported randomized controlled trials have studied the effect of intradiscal biologic injections. Here we report single-center outcomes from these trials to determine if there is clinical improvement associated with these intradiscal injections.

METHODS

Post hoc comparison was performed using single-site data from 4 similar multi-center randomized controlled trials. All trials evaluated an injectable therapy (growth factor, fibrin sealant, or stem cells) for symptomatic lumbar disc disease with near-identical inclusion and exclusion criteria. Demographics and patient reported outcomes were analyzed across treatment arms postinjection.

RESULTS

A total of 38 patients were treated with biologic agents and 12 were treated with control saline injections. There was a significant decrease in visual analogue score (VAS) pain for both the investigational and saline groups up to 12 months postinjection ( < .01). There was no significant difference in VAS scores between the saline and investigational groups at 12 months. Similarly, there was significant improvement in patient-reported disability scores in both the investigational and saline groups at all time points. There were no significant differences in disability score improvement between the saline and investigational treatment groups at 12 months postinjection.

CONCLUSIONS

A single-center analysis of 4 randomized controlled studies demonstrated no difference in outcomes between therapeutic intradiscal agents (growth factor, fibrin sealant, or stem cells) and control saline groups. In all groups, patient reported pain and disability scores decreased significantly. Future studies are needed to evaluate the therapeutic benefit of any intradiscal injections.

摘要

研究设计

使用来自4项多中心随机对照试验的单中心数据进行事后比较。

目的

椎间盘源性背痛与显著的发病率和医疗费用相关。几项已终止但未报告的随机对照试验研究了椎间盘内生物注射的效果。在此,我们报告这些试验的单中心结果,以确定这些椎间盘内注射是否与临床改善相关。

方法

使用来自4项相似的多中心随机对照试验的单中心数据进行事后比较。所有试验均评估了一种可注射疗法(生长因子、纤维蛋白密封剂或干细胞)用于症状性腰椎间盘疾病,纳入和排除标准几乎相同。在注射后对各治疗组的人口统计学和患者报告的结果进行分析。

结果

共有38例患者接受了生物制剂治疗,12例接受了对照生理盐水注射。在注射后长达12个月的时间里,研究组和生理盐水组的视觉模拟评分(VAS)疼痛均显著降低(P <.01)。在12个月时,生理盐水组和研究组的VAS评分无显著差异。同样,在所有时间点,研究组和生理盐水组患者报告的残疾评分均有显著改善。在注射后12个月,生理盐水治疗组和研究治疗组之间的残疾评分改善无显著差异。

结论

对4项随机对照研究的单中心分析表明,治疗性椎间盘内药物(生长因子、纤维蛋白密封剂或干细胞)与对照生理盐水组之间的结果无差异。在所有组中,患者报告的疼痛和残疾评分均显著降低。需要进一步的研究来评估任何椎间盘内注射的治疗益处。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/830a/9344499/f633762885b2/10.1177_2192568220963058-fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验